Indications: Indicated for the treatment of adults with Type 2 Dabetes Mellitus as an adjunct to diet and exercise.

Evania M 12.5/ 500 is a combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and metformin hydrochloride, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin hydrochloride is appropriate.Evania M 12.5/ 500 is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of Evania M 12.5/ 500 on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been...

By blocking SGLT2, empagliflozin prevents glucose from being reabsorbed and allows it to be excreted in the urine and decreasing the production of glucose in the liver and increasing the sensitivity of cells to insulin .It work synergistically to lower blood sugar levels more effectively.